Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brinzolamide/Timolol · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Brinzolamide/Timolol | DRUG | - |
Inclusion Criteria: * Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) Exclusion Criteria: * Under 18
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Brinzolamide/Timolol is an investigational fixed-dose combination being studied for the treatment of open-angle glaucoma. It is also being evaluated in patients with ocular hypertension. The drug is administered as a topical ophthalmic therapy and is currently in Phase 2 clinical development.
Brinzolamide/Timolol is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device and pharmaceutical company focused on eye care, and it is conducting clinical research on this combination therapy for glaucoma.
Brinzolamide/Timolol is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under investigation for the treatment of open-angle glaucoma and ocular hypertension.
Brinzolamide/Timolol has been studied in one completed Phase 2 clinical trial, registered under the identifier NCT00326092. The trial enrolled 88 participants in the United States and evaluated the therapy in patients with open-angle glaucoma or ocular hypertension. The study was randomized and double-blind.
Brinzolamide/Timolol is a fixed-dose combination product that contains two active ingredients: brinzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker. This combination is being developed to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension.